Vantage BioTrials awarded “Biotechnology CRO of the Year 2018 – Quebec”

MONTREAL, August 20, 2018 – Vantage BioTrials has been named the “Biotechnology CRO of the Year 2018 – Quebec” by GHP Magazine.

Vantage BioTrials is a full-service CRO based in Canada that provides Phase I-IV clinical trial management services to pharmaceutical, biotechnology and medical device companies and with operational capabilities across North America, Latin America, and Europe. Viken Bartekian, Vice-President, Corporate Development, explains more.

Vantage BioTrials boasts a wealth of knowledge and experience with its expertise running clinical trials throughout a full range of therapeutic areas, and its strength lies within its lean management strategies and operations for conducting clinical studies in the most efficient, targeted fashion, ensuring the best results for clients every time.

Thanks to its innovative approach, the company has won numerous industry awards over the last 11 years of operations, and is happy to count GHP’s “Biotechnology CRO of the Year 2018 – Quebec” among them. Viken explores the firm’s incredible success in more detail and outlines how it works to ensure it continues to achieve excellence in every aspect of its work.

“Since inception, our mission at Vantage BioTrials has been to use innovative clinical trial management strategies for the life science industry with a focus on patient safety and advancing new therapies to market. We understand the importance of speed in healthcare and incorporating different strategies to utilize the best technologies and processes so that ground-breaking therapies can get to patients faster. This award is timely as our market focus has recently shifted towards helping smaller life science firms bring their novel therapies to later-phases of research.”

To gain an insight into the firm’s future plans, we spoke to Vatche Bartekian, President, who was excited for what the future holds for Vantage BioTrials.

“As a very important step for the future growth of our company and as part of our dedication for adhering to quality principles in our day-to-day operations which is reflected in our approach to work transparently with Canada’s Health Authority, we recently volunteered to partake in a first of its kind pilot inspection program by Health Canada which took place in May 2018.”

Vatche continues to add, “As one of the first Clinical Trial Management CRO’s to be inspected by Health Canada, we gained clear insight on how they (Health Canada) want risk-based clinical monitoring, risk-based management and Quality by Design implementation of early & late phase studies to be performed. The inspection results of our systems, processes & sponsor specific studies were positive and constructive.  We look forward to continuing our open and transparent communications with Canada’s Health Authority and sharing our unique experience in the coming months.”

To read the full article by GHP Magazine, click here.

About us

Founded in 2007, Vantage BioTrials is a privately-held Contract Research Organization (CRO) that provides Phase I-IV clinical trial management services and implements Risk-Based Management through the use of Quality by Design (QbD) methodologies, all delivered to international pharmaceutical, biotechnology, generic pharmaceutical and medical device companies.

Follow us on LinkedIn and Twitter.

Tags:
Categorynews